- Home
- / Syros Pharmaceuticals
Syros Pharmaceuticals
Stock Price
$2.5
2024-10-29
Market Capitalization
$67.8 M
2024-10-29
Revenue
$9.9 M
FY, 2023
Syros Pharmaceuticals Summary
Company Summary
- Overview
- Syros Pharmaceuticals is a life sciences company that is focused on treating diseases by mapping gene regulatory circuits. It is engaged in pharmaceutical development for treating myelodysplastic syndrome, acute myeloid and promyelocytic leukemia, pancreatic cancer, and other diseases.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Cambridge, MA, US | view all locations
- Website
- http://syros.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jason Haas, Chief Financial Officer
David A. Roth, Chief Medical Officer
Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
LocationsView all
1 location detected
Cambridge, MA HQ
United States
35 Cambridgepark Dr 4th floor
Syros Pharmaceuticals Financials
Summary Financials
- Net income (Q3, 2024)
- ($6.4M)
- Cash (Q3, 2024)
- $58.3M
- EBIT (Q3, 2024)
- ($26.2M)
- Enterprise value
- $69.8M